



*Innovating Mental Health and Wellness*

Next Level Health Sciences is an early stage mushroom company focused on:

- 0.1 creating technology** our competitors can license
- 0.2 developing drugs** that help promote health
- 0.3 providing products** for non-medical consumers



Investor Presentation  
Summer 2020

# Disclaimer

---

This proprietary and confidential document (the “presentation”) is provided by Next Level Health Services (the “Company”). The presentation is only for informational purposes. The presentation may not be copied, distributed, reproduced, discussed or used without the express written consent of the Company, or for any other purpose than the evaluation of a possible investment in the Company by the recipient. Relying on the presentation for the purpose of investment activity of any type may expose an individual to significant risk of losing some or all of the property or other assets invested. In providing the presentation to the recipient, the Company and its advisors reserve the right to provide the same or similar information to other recipients and to enter into agreements with other parties regarding the opportunity described in the presentation, and to cease to provide the recipient with information on the opportunity, all without notice to the recipient.

The presentation is not intended as an offer or solicitation with respect to the purchase or sale of any financial instrument. If a private placement of the equity securities of the Company occurs, such transaction may not be registered under the Securities Act of 1933, as amended (the “Act”), or the securities laws of any other jurisdiction, and would be conducted in reliance on exemptions from the registration requirements of the Act and other applicable laws and subject to selling and transfer restrictions.

The presentation is not, and under no circumstances is to be construed as, a prospectus, an advertisement, or a public offering of securities in the United States of America, in Canada, or in any other jurisdiction. No securities commission or similar authority of the United States, Canada, or any other jurisdiction has reviewed or in any way passed upon this document or the merits of the securities described within the presentation, and any representation to the contrary is an offence.

The Company does not make any representation or warranty as to the accuracy or completeness of the information in the presentation. The information within the presentation may not be relied upon by the recipient in evaluating the merits of investing in any securities referred to herein. The presentation does not contain, nor does it purport to contain, a summary of all the material information concerning the Company or the terms and conditions of any potential investment in the Company. If and when the recipient determines to proceed with investigations and discussions regarding a possible investment in the Company, the recipient is urged to carry out independent investigations to determine the recipient’s interest in investing in the Company.

The presentation does not contain all of the information that would normally appear in a prospectus under applicable United States or Canadian securities laws. Neither the delivery of the presentation, at any time, nor any sale made pursuant hereto, will imply that the information contained herein is correct as of any time subsequent to the date indicated on the first page of the presentation or the date at which such information is expressed to be stated, as applicable, and, except as may be required by applicable law, the Company is under no obligation to update any of the information contained herein, including forward looking statements and forward looking information, or to inform the recipient of any matters of which the Company becomes aware that may affect any matter referred to in the presentation, including, but not limited to, any error or omission which may become apparent after the presentation has been prepared.

Investing in the Company involves significant risks in light of the Company’s early stage nature. Prior to investing in the Company, the recipient is urged to consult with their legal, accounting, investment, tax and other advisors to determine the risks and consequences of such an investment. Prospective investors should not construe the contents of the presentation as investment or legal advice.

The presentation contains certain forward-looking statements and forward-looking information. Forward-looking statements are frequently, but not always, identified by words such as “expects,” “anticipates,” “believes,” “intends,” “estimates,” “potential,” “possible,” “projects,” “plans,” and similar expressions, or statements that events, conditions or results “will,” “may,” “could,” or “should” occur or be achieved or their negatives or other comparable words. Any forward-looking statements made herein or made elsewhere by the Company are made solely based on information available to the Company as of the date hereof and based only on the Company’s current beliefs, expectations and assumptions regarding the future of its business, anticipated events and trends, the economy and other future conditions. As such, they are subject to inherent uncertainties, risks, assumptions and changes in circumstances that are difficult to predict, including but not limited to risks applicable to early stage ventures, and in many cases outside of the Company’s control, and the recipient should not rely on such forward-looking statements. All statements other than statements of historical fact could be deemed forward-looking, including, but not limited to, any statements about historical results that suggest trends for the Company’s business, any statements of plans, strategies and objectives of management and any statements of expectation or belief regarding future events. “Future-oriented financial information” is forward-looking information about prospective results of operations, financial position or cash flows, based on assumptions about future economic conditions and courses of action, and presented in the format of a historical statement of financial position, statement of comprehensive income or statement of cash flows. Similarly, a “financial outlook” is forward-looking information about prospective financial performance, financial position or cash flows that is based on assumptions about future economic conditions and courses of action that is not presented in the format of a historical statement of financial position, statement of comprehensive income or statement of cash flows. Future-oriented financial information and financial outlook made herein or made elsewhere by the Company are made solely based on the information available to the Company as of the date hereof and are subject to the same assumptions, risk factors and other qualifications as all other forward-looking information, and presented solely for the purpose of conveying the current anticipated expectations of the Company and may not be appropriate for any other purposes. Forward-looking statements and forward-looking information address future events and conditions and therefore involve inherent known and unknown risks and uncertainties. Actual results may differ materially from those in the forward-looking statements and forward-looking information due to risks facing the Company, or due to actual facts differing from the assumptions underlying its predictions.

Certain of the information contained in the presentation concerning the industry and its trends and performance is based upon or derived from information provided by third-party consultants, other industry sources, and our research. The Company believes such information is accurate and that the sources from which it has been obtained are reliable. However, the Company cannot guarantee the accuracy of such information and has not independently verified the assumptions upon which any projections are based.

## Focus: Three Verticals

Next Level Health Sciences (“Next Level”) is an early stage Canadian based company exclusively dedicated to the growing international medical and functional mushroom sector.

We are focused on:

- 0.1 creating technology** our competitors can license
- 0.2 developing drugs** that help promote health
- 0.3 providing products** for non-medical consumers

### 01. Licensable Technology Next Level Bioscience

“Pick and shovel” model where competitors in the mushroom sector can license our technology to enhance the delivery and performance of their drugs and products.



### 02. Pharmaceutical Next Level Therapeutics

Focused R&D toward the development of novel indication drugs and medicines that target unmet needs or conditions lacking effective modern treatments.



### 03. Nutraceuticals Next Level Brands

Drive near-term revenue through the development and supply of non-regulated functional mushrooms and food products that provide health and wellness support.




## 01. Licensable Technology: Problem



Similar to cannabis edibles, mushroom products have four problems:

1. Onset takes too long
2. Dose magnitude is inconsistent or difficult to predict
3. The effects last too long
4. They commonly create gastrointestinal distress and can be distasteful




## 01. Licensable Technology: Solution




Our preliminary experimentations with non-psychoactive mushrooms indicate the potential for a breakthrough technology that competitors could license and integrate with their regulated medicinal drugs or unregulated functional products to enhance the effectiveness and user experience.

Our results to date include:

- Digestion time reduced
- Duration of effects shortened substantially
- Absorption amplified by 700-1000% (reduces quantity required, which reduces gastrointestinal distress and improves product flavor)



# 01. Licensable Technology: Milestone Roadmap




## 02. Pharmaceutical



We are focused on R&D toward the development of novel indication drugs and medicines that target unmet needs or conditions lacking effective modern treatments.

- **Initial Focus:** Discover R&D gaps and opportunities in mental illness and the health sector where mushroom-based formulations could provide unique solutions
- **Potential Target Conditions:** addiction, depression, anxiety, TBI (traumatic brain injury), dementia, OCD, ADHD, among others
- **R&D Program Approach:** Collaborate with leading research lab, CRO (contract research organization) or institution
- **End Goal:** Create IP and develop patent portfolio in psychedelic drug space
- **Potential Competitive Advantage:** Leverage progress made toward our technology for enhancing drug delivery and performance

### Global Economic Cost of Mental Disorders



### Global Health Medications: USD \$88B

*Depression is the leading cause of disability worldwide (264M+ sufferers), with a total annual economic burden of \$210B in the US alone.*

– The American Psychiatric Association

*The largest acquisitions in the pharma industry over the past 10 years exceed a total of \$775B.*

### 03. Nutraceuticals



We are focused on driving near-term revenue through the development and supply of non-regulated functional mushrooms and food products that provide health and wellness support.

We intend to sell our products through online and brick-and-mortar retailers.

We are currently exploring two models with speed-to-market being the primary consideration:

- Source leading manufacturers of functional mushroom products in the US, Canada and Europe to manufacture, co-pack and distribute products unique to Next Level Brands in those regions
- Leverage existing white label products and their related sales and distribution channels to bring Next Level Brands products to the market

#### Global Nutraceutical Market

**2019:** USD \$382B

**2027:** USD \$722B (projected)

**CAGR:** 8.3% (projected through 2027)

*“Demand for functional foods is on the rise as they are believed to impart exceptional health benefits owing to their nutrient content.”*

– Grand View Research, April 2020








*“The application of these mushrooms as a functional ingredient in the medical industry is driving the growth of the market, as functional mushrooms are being increasingly incorporated into health supplements.”*

– Research and Markets, April 2020





## Comparables

							
<b>Focus</b>	Licensable Tech, R&D, Branded Products	R&D Branded Products	Branded Products	R&D	Research & Clinics	Clinical Trials	Clinical Trials
<b>Market</b>	Health & Wellness; Medicinal	Health & Wellness	Health & Wellness	Medicinal	Medicinal	Medicinal	Medicinal
<b>Status</b>	Private	IPO Q2 2020	Public	Public	Public	Public	Private
<b>Value</b>	Currently raising capital	Market Cap: C\$13.25M*	Market Cap: C\$97M	Market Cap: C\$51M	Market Cap: C\$52M	Market Cap: C\$92M	Capital Raised: \$116M

Market caps from June 4, 2020.

\*Anticipated pro forma market capitalization post-listing and assuming completion of the various financings referenced on the following page (from HAVNLIFE's Investor Deck 2020).


## Market

### Expanding Functional Mushroom Opportunity



**Targeted Global Functional Food Market:** USD \$34.4B by 2024  
**CAGR:** 8.04% during forecast period (2019-2024)

*Source: Global Functional Mushroom Market to 2024, Research and Markets*



### Psychedelics Regulations Opening Up



**2019:** FDA approves first drug from a psychedelic, Johnson & Johnson's *Spravato* for treatment-resistant depression with expected annual revenue of \$1.3B

**2019:** FDA grants second psilocybin study "breakthrough therapy" status to accelerate the development and review process

*"Psychedelics have been a mainstay for a millennia and appreciated in the counter-culture for decades. In 2020, whether consuming, investing, or both, mushrooms are having a moment."*

– Forbes, Jan. 2020

## Team

---

Next Level represents a team of proven business, technology and product developers focused on the emerging mushroom market.

### **David Weinkauf, Founder & Interim CEO, Director**

Mr. Weinkauf is a strategic businessman who has been working in the nutraceutical, pharmaceutical and functional brands market for the last two years, and in the IP/patent space for the last four years.

As a self starter he has been involved in numerous private and public entities focused on identifying unique opportunities, investment, strategic development and growth of those companies. In addition to having been involved in roughly \$3.0 Billion in real estate development and transactions, David has founded current start-ups in disruptive technologies, is the inventor of a number of products under multiple provisional patent applications in the U.S., and volunteers his time to noteworthy causes.

Mr. Weinkauf has been a co-founder and past director of a U.S. publicly traded cannabis company and currently is a co-founder and director of a Canadian Capital Pool Company trading as SARG:TSXv. David holds a B.Comm. from the University of Calgary, is recognized as Calgary's Top 40 under 40 alumni, and was nominated for Canada's top 40 under 40 during his career.

### **Anthony Zelen, Business Development, Director**

Mr. Zelen is a serial entrepreneur who has over 23 years of experience in finance, investor relations, sales, and corporate development. He was the owner and president of Senergy Communications Inc., which focused on the public markets and was involved in investor relations, public relations and strategic marketing for the technology, cannabis, pharmaceutical, mining and oil and gas industries.

Mr. Zelen has served as officer and director of at least 12 publicly listed companies over the last 21 years. His business activities within the venture capital arena enabled him to establish a network of accredited investors, angel investors and investment banking contacts throughout North America, Europe and Asia.

Over the last 23 years Mr. Zelen has been involved in no less than a dozen startups including Diitalk Communications, a co-founder of Blockchain Intelligence Group, and founding member of Allied Corp.

### **Mark Scott, CTO, Director**

With a background in computer science, Mr. Scott founded and ran a technology and automation company for 13 years. His company, New Space Technologies, won several international awards for innovation and best practices.

In 2016 he was encouraged to explore technologies in the cannabis industry.

In 2017 he founded Activated Nano, a food science company focused on the cannabis edibles market. Their first product, SureNano, was selected by global food ingredients supplier, Caldic, and is launching in 2020 in North America under a manufacturing and distribution agreement.

Mr. Scott continues to drive innovation and growth for Activated Nano while looking to expand his involvement in consumer products for the cannabis and the emerging psychedelics industry.

## Team

---

Next Level represents a team of proven business, technology and product developers focused on the emerging mushroom market.

### **Malcolm Davidson, CFO, Director**

Mr. Davidson has over 16 years of experience in finance, tax, financial accounting and assurance. As a chartered Professional Accountant, he brings years of professional experience to public companies listed on the TSX and NYSE.

Mr. Davidson has experience in many industries, including having served as CFO for multiple publicly traded companies in the highly regulated cannabis space.

He specializes in the following areas: financing and capital raises, financial reporting and regulatory compliance, corporate governance, mergers and acquisitions, developing and implementing internal control systems, financial reporting and compliance, assisting companies with upgrading their listings in Canada and the United States, and marketing companies for the purposes of raising capital via roadshows and conferences.

## Pre-IPO Use of Proceeds

Seeking \$300,000 CDN for pre-IPO R&D and operations rollout.

<b>Lab</b>	\$50,000
<b>Equipment &amp; Supplies</b>	\$60,000
<b>Filings &amp; Patents</b>	\$45,000
<b>Admin &amp; Operations</b>	\$60,000
<b>Legal</b>	\$15,000
<b>Accounting &amp; Bookkeeping</b>	\$5,000
<b>Management &amp; Consulting</b>	\$65,000

This is a pre-IPO round. IPO financing use of proceeds and details will be available upon request.




*Innovating Mental Health and Wellness*

---

Next Level Health Sciences is an early stage mushroom company focused on:

- 0.1 creating technology** our competitors can license
- 0.2 developing drugs** that help promote health
- 0.3 providing products** for non-medical consumers



**Contact Us**

Anthony Zelen, Business Development, Director

T: 1-778-388-5258

E: [anthony@nextlevelhealthsciences.com](mailto:anthony@nextlevelhealthsciences.com)